

# Grand Rounds

Friday, February 9, 9:00am

## The Impact of Therapy on Glioma Evolution

*featuring*

**Roel Verhaak, PhD**

**Associate Director of Computational Biology,  
Department of Neurosurgery**

55 Park Street Auditorium | [Zoom](#) Access  
Continental breakfast will be available

**Needs:** Understanding how commonly used treatments may alter the behavior of gliomas may improve outcomes for patients with a glioma.

**Objectives:** Describe commonly used therapies for treatment of patients with a glioma. Describe how therapies for glioma treatment can drive changes in response in recurrent disease. Nominate approaches to optimize treatment strategies for patients with a glioma.



Continuing Medical Education  
Yale CME



Dr. Roel Verhaak is a Professor in the Department of Neurosurgery at the Yale School of Medicine. He received his PhD from the Erasmus University Medical Center in Rotterdam, the Netherlands and as a postdoctoral associate at Broad Institute/Dana-Farber Cancer, he was part of the team analyzing data from The Cancer Genome Atlas. There he led the identification and characterization of gene expression subtypes in glioblastoma, work that resulted in a seminal Cancer Cell 2010 publication.

His lab currently studies tumor evolution and mechanisms of therapy resistance in low- and high-grade gliomas. After being affiliated with the Jackson Laboratory for Genomic Medicine, the Verhaak lab joined the School of Medicine in 2023. Dr. Verhaak is a recipient of the AAAS Wachtel Award, the Agilent Early Career Professor Award, and the Peter Steck Memorial Award, and is a co-founder of Boundless Bio.